PREM - Q2 commissioning - Lithium/Spodumene +64% YTD5 May 2026 08:35
Q2 commissioning is a major near term catalyst, on success the market will forward price a lot of upside almost instantly. The shift to Xinhai (a larger China based, lithium experienced EPC contractor) marks a clear upgrade from the earlier Stark (Western, smaller) built setup, which struggled to deliver consistent performance. At circa £5M market cap, if the new flotation plant achieves steady state operation, the re rating potential is significant given it traded at £225M. Two TR1's have cornered over 18% of the float in the past month.
Spodumene prices are up 64% YTD and at around $2,540/t SC6, the new Xinhai plant is designed for 15–20 tph of ore feed, or 131,000–175,000 tonnes of ore per year, based on 1.7% feed grade and 80–90% recovery from testwork, producing SC6 concentrate.
That points to estimated SC6 production of roughly 35,000–45,000 tonnes per year, generating approximately $89M–$114M in annual revenue at current pricing. With operating costs around $800–$1,200/t SC6, this implies roughly $60M–$80M EBITDA potential, assuming recovery, grade, and throughput can be maintained consistently. On a conservative PE multiple of 5x EBITDA, that implies roughly $300M–$400M valuation (1–1.25p), while at 8x EBITDA, that moves to $480M–$640M (1.5–2p).